Literature DB >> 22794159

Drug delivery systems with modified release for systemic and biophase bioavailability.

Sorin E Leucuta1.   

Abstract

This review describes the most important new generations of pharmaceutical systems: medicines with extended release, controlled release pharmaceutical systems, pharmaceutical systems for the targeted delivery of drug substances. The latest advances and approaches for delivering small molecular weight drugs and other biologically active agents such as proteins and nucleic acids require novel delivery technologies, the success of a drug being many times dependent on the delivery method. All these dosage forms are qualitatively superior to medicines with immediate release, in that they ensure optimal drug concentrations depending on specific demands of different disease particularities of the body. Drug delivery of these pharmaceutical formulations has the benefit of improving product efficacy and safety, as well as patient convenience and compliance. This paper describes the biopharmaceutical, pharmacokinetic, pharmacologic and technological principles in the design of drug delivery systems with modified release as well as the formulation criteria of prolonged and controlled release drug delivery systems. The paper presents pharmaceutical prolonged and controlled release dosage forms intended for different routes of administration: oral, ocular, transdermal, parenteral, pulmonary, mucoadhesive, but also orally fast dissolving tablets, gastroretentive drug delivery systems, colon-specific drug delivery systems, pulsatile drug delivery systems and carrier or ligand mediated transport for site specific or receptor drug targeting. Specific technologies are given on the dosage forms with modified release as well as examples of marketed products, and current research in these areas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22794159     DOI: 10.2174/157488412803305786

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  4 in total

Review 1.  Axon-soma communication in neuronal injury.

Authors:  Ida Rishal; Mike Fainzilber
Journal:  Nat Rev Neurosci       Date:  2013-12-11       Impact factor: 34.870

2.  Mutant KRAS is a druggable target for pancreatic cancer.

Authors:  Elina Zorde Khvalevsky; Racheli Gabai; Itzhak Haim Rachmut; Elad Horwitz; Zivia Brunschwig; Ariel Orbach; Adva Shemi; Talia Golan; Abraham J Domb; Eylon Yavin; Hilla Giladi; Ludmila Rivkin; Alina Simerzin; Rami Eliakim; Abed Khalaileh; Ayala Hubert; Maor Lahav; Yael Kopelman; Eran Goldin; Alan Dancour; Yael Hants; Sagit Arbel-Alon; Rinat Abramovitch; Amotz Shemi; Eithan Galun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

Review 3.  Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.

Authors:  Min Li; Sanna Sander; John Duan; Susan Rosencrance; Sarah Pope Miksinski; Lawrence Yu; Paul Seo; Bhagwant Rege
Journal:  AAPS J       Date:  2016-09-20       Impact factor: 4.009

4.  Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.

Authors:  N A Nikitenko; V S Prassolov
Journal:  Acta Naturae       Date:  2013-07       Impact factor: 1.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.